Results of a multicenter study of nebulized inhalant bronchodilator solutions

D. P. Tashkin, E. Bleecker, S. Braun, S. Campbell, A. C. DeGraff, D. W. Hudgel, Michael Boyars, S. Sahn

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The efficacy, persistence of bronchodilator action, and safety of the quaternary ammonium anticholinergic agent, ipratropium bromide (500 μg), and placebo were compared when each was added in solution form to the β- adrenergic agonist solution, metaproterenol sulfate (15 mg), and administered three times daily for 12 weeks to a total of 213 patients with chronic obstructive pulmonary disease (COPD). Subjects had a mean forced expiratory volume in 1 second (FEV1) of approximately 1 liter (37% of predicted) and were permitted to use nonanticholinergic therapy for COPD throughout the trial. The study was a randomized, double-blind, 85-day, parallel-group, eight-center study. On 3 test days, 1, 43, and 85, mean peak responses for FEV1 and forced vital capacity and mean area under the curve were significantly higher for the ipratropium bromide-metaproterenol combination than for metaproterenol only. Duration of action was also significantly longer for the combination therapy than for the β-agonist alone on test days 1 and 43. Neither treatment regimen produced any demonstrable effect on daily morning peak expiratory flow rates, reported respiratory symptoms, or quality of life. Both treatment regimens were similarly well tolerated with a comparable frequency of adverse events. These results suggest that the combination of ipratropium bromide and metaproterenol inhalation solutions offers a potential therapeutic advantage to patients with symptomatic COPD over nebulized metaproterenol alone without the risk of increased side effects.

Original languageEnglish (US)
Pages (from-to)S62-S69
JournalAmerican Journal of Medicine
Volume100
Issue number1 A
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Metaproterenol
Bronchodilator Agents
Multicenter Studies
Ipratropium
Chronic Obstructive Pulmonary Disease
Forced Expiratory Volume
Therapeutics
Peak Expiratory Flow Rate
Adrenergic Agonists
Vital Capacity
Cholinergic Antagonists
Ammonium Compounds
Inhalation
Area Under Curve
Placebos
Quality of Life
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tashkin, D. P., Bleecker, E., Braun, S., Campbell, S., DeGraff, A. C., Hudgel, D. W., ... Sahn, S. (1996). Results of a multicenter study of nebulized inhalant bronchodilator solutions. American Journal of Medicine, 100(1 A), S62-S69.

Results of a multicenter study of nebulized inhalant bronchodilator solutions. / Tashkin, D. P.; Bleecker, E.; Braun, S.; Campbell, S.; DeGraff, A. C.; Hudgel, D. W.; Boyars, Michael; Sahn, S.

In: American Journal of Medicine, Vol. 100, No. 1 A, 01.01.1996, p. S62-S69.

Research output: Contribution to journalArticle

Tashkin, DP, Bleecker, E, Braun, S, Campbell, S, DeGraff, AC, Hudgel, DW, Boyars, M & Sahn, S 1996, 'Results of a multicenter study of nebulized inhalant bronchodilator solutions', American Journal of Medicine, vol. 100, no. 1 A, pp. S62-S69.
Tashkin DP, Bleecker E, Braun S, Campbell S, DeGraff AC, Hudgel DW et al. Results of a multicenter study of nebulized inhalant bronchodilator solutions. American Journal of Medicine. 1996 Jan 1;100(1 A):S62-S69.
Tashkin, D. P. ; Bleecker, E. ; Braun, S. ; Campbell, S. ; DeGraff, A. C. ; Hudgel, D. W. ; Boyars, Michael ; Sahn, S. / Results of a multicenter study of nebulized inhalant bronchodilator solutions. In: American Journal of Medicine. 1996 ; Vol. 100, No. 1 A. pp. S62-S69.
@article{4618632c953649228ff231d9254b4acb,
title = "Results of a multicenter study of nebulized inhalant bronchodilator solutions",
abstract = "The efficacy, persistence of bronchodilator action, and safety of the quaternary ammonium anticholinergic agent, ipratropium bromide (500 μg), and placebo were compared when each was added in solution form to the β- adrenergic agonist solution, metaproterenol sulfate (15 mg), and administered three times daily for 12 weeks to a total of 213 patients with chronic obstructive pulmonary disease (COPD). Subjects had a mean forced expiratory volume in 1 second (FEV1) of approximately 1 liter (37{\%} of predicted) and were permitted to use nonanticholinergic therapy for COPD throughout the trial. The study was a randomized, double-blind, 85-day, parallel-group, eight-center study. On 3 test days, 1, 43, and 85, mean peak responses for FEV1 and forced vital capacity and mean area under the curve were significantly higher for the ipratropium bromide-metaproterenol combination than for metaproterenol only. Duration of action was also significantly longer for the combination therapy than for the β-agonist alone on test days 1 and 43. Neither treatment regimen produced any demonstrable effect on daily morning peak expiratory flow rates, reported respiratory symptoms, or quality of life. Both treatment regimens were similarly well tolerated with a comparable frequency of adverse events. These results suggest that the combination of ipratropium bromide and metaproterenol inhalation solutions offers a potential therapeutic advantage to patients with symptomatic COPD over nebulized metaproterenol alone without the risk of increased side effects.",
author = "Tashkin, {D. P.} and E. Bleecker and S. Braun and S. Campbell and DeGraff, {A. C.} and Hudgel, {D. W.} and Michael Boyars and S. Sahn",
year = "1996",
month = "1",
day = "1",
language = "English (US)",
volume = "100",
pages = "S62--S69",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "1 A",

}

TY - JOUR

T1 - Results of a multicenter study of nebulized inhalant bronchodilator solutions

AU - Tashkin, D. P.

AU - Bleecker, E.

AU - Braun, S.

AU - Campbell, S.

AU - DeGraff, A. C.

AU - Hudgel, D. W.

AU - Boyars, Michael

AU - Sahn, S.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - The efficacy, persistence of bronchodilator action, and safety of the quaternary ammonium anticholinergic agent, ipratropium bromide (500 μg), and placebo were compared when each was added in solution form to the β- adrenergic agonist solution, metaproterenol sulfate (15 mg), and administered three times daily for 12 weeks to a total of 213 patients with chronic obstructive pulmonary disease (COPD). Subjects had a mean forced expiratory volume in 1 second (FEV1) of approximately 1 liter (37% of predicted) and were permitted to use nonanticholinergic therapy for COPD throughout the trial. The study was a randomized, double-blind, 85-day, parallel-group, eight-center study. On 3 test days, 1, 43, and 85, mean peak responses for FEV1 and forced vital capacity and mean area under the curve were significantly higher for the ipratropium bromide-metaproterenol combination than for metaproterenol only. Duration of action was also significantly longer for the combination therapy than for the β-agonist alone on test days 1 and 43. Neither treatment regimen produced any demonstrable effect on daily morning peak expiratory flow rates, reported respiratory symptoms, or quality of life. Both treatment regimens were similarly well tolerated with a comparable frequency of adverse events. These results suggest that the combination of ipratropium bromide and metaproterenol inhalation solutions offers a potential therapeutic advantage to patients with symptomatic COPD over nebulized metaproterenol alone without the risk of increased side effects.

AB - The efficacy, persistence of bronchodilator action, and safety of the quaternary ammonium anticholinergic agent, ipratropium bromide (500 μg), and placebo were compared when each was added in solution form to the β- adrenergic agonist solution, metaproterenol sulfate (15 mg), and administered three times daily for 12 weeks to a total of 213 patients with chronic obstructive pulmonary disease (COPD). Subjects had a mean forced expiratory volume in 1 second (FEV1) of approximately 1 liter (37% of predicted) and were permitted to use nonanticholinergic therapy for COPD throughout the trial. The study was a randomized, double-blind, 85-day, parallel-group, eight-center study. On 3 test days, 1, 43, and 85, mean peak responses for FEV1 and forced vital capacity and mean area under the curve were significantly higher for the ipratropium bromide-metaproterenol combination than for metaproterenol only. Duration of action was also significantly longer for the combination therapy than for the β-agonist alone on test days 1 and 43. Neither treatment regimen produced any demonstrable effect on daily morning peak expiratory flow rates, reported respiratory symptoms, or quality of life. Both treatment regimens were similarly well tolerated with a comparable frequency of adverse events. These results suggest that the combination of ipratropium bromide and metaproterenol inhalation solutions offers a potential therapeutic advantage to patients with symptomatic COPD over nebulized metaproterenol alone without the risk of increased side effects.

UR - http://www.scopus.com/inward/record.url?scp=34547229866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547229866&partnerID=8YFLogxK

M3 - Article

C2 - 8610720

AN - SCOPUS:34547229866

VL - 100

SP - S62-S69

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 1 A

ER -